Subgroup analysis of Japanese patients in a Phase 3 study of atezolizumab in advanced triple-negative breast cancer (IMpassion130)

BACKGROUND: In the randomised Phase 3 IMpassion130 trial, atezolizumab combined with nab-paclitaxel (atezo + nab-P) in 902 patients with triple-negative breast cancer (TNBC) showed prolonged progression-free survival (PFS) in both the intention-to-treat (ITT) population and programmed death-ligand 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwata, Hiroji, Inoue, Kenichi, Kaneko, Koji, Ito, Yoshinori, Tsugawa, Koichiro, Hasegawa, Ayumi, Nakagawa, Shintaro, Kuratomi, Hiroyasu, Tamura, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935297/
https://www.ncbi.nlm.nih.gov/pubmed/31612909
http://dx.doi.org/10.1093/jjco/hyz135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935297/
https://www.ncbi.nlm.nih.gov/pubmed/31612909
http://dx.doi.org/10.1093/jjco/hyz135

Ejemplares similares